MCAM and prostate carcinoma: To support this notion, we have found that METCAM promotes the progression of prostate cancer cells by rendering the cells with increased proliferative ability by elevating levels of Ki67 and PCNA, with increased survival ability by elevating the level of phosphorylated AKT, and with increased angiogenic ability by elevating levels of VEGF, VEGFR2, and CD31 [35]; but it has no effect on the process of apoptosis.